Current medical news and unique business news for anyone who cares about healthcare.
NSF incubator boot camp. For any researchers wanting to take their ideas to market themselves, there’s a new program that might be able to help. The National Science Foundation Innovation Corps program, just announced yesterday, is a new public-private program aiming to take innovative healthcare ideas to market. Innovation Corps, or I-Corps, will offer $50,000 grants and put scientists through a curriculum on startups to help them turn their innovative healthcare ideas into healthcare business ventures. Check out the announcement video below.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell court case. A federal judge has upheld taxpayer money being used for stem-cell research. Two scientists had brought a lawsuit on the topic after President Obama undid former President Bush’s restriction on funding for such studies in 2009.
Questioning mammograms…again. Better breast cancer drug treatments, rather than more testing, is likely responsible for the recent drop in breast cancer deaths in Europe. Mammograms played no direct part in reducing deaths, according to a new study in the British Medical Journal. The question of when and how often should women get mammograms has been a hotly debated topic over the past year.
Super flu vaccine coming into view. British researchers appear to have found a super flu antibody that could fight off all main types of influenza A virus. Currently, flu shot makers have to reformulate their vaccines each year to ensure they are fighting the strains that are currently circulating.
Drugmakers defend experimental diabetes drug. Eli Lily, Amylin and Alkermes completed studies requested by the FDA and submitted an official response to the FDA regarding their experimental diabetes drug Bydureon. A spokesman says the study results address the issues raised by the FDA, and the companies hope to see Bydureon available to patients as soon as possible.
